摘要
前列腺癌根治性前列腺切除术(RRP)术后勃起功能障碍(ED)的发生率10%～100%,保留神经的根治性前列腺切除术(NS-RRP)术后ED也超过三分之一.5型磷酸二酯酶(PDE5)抑制剂可用于各种原因ED的治疗.西地那非、伐地那非和他达拉非临床应用显示对RRP术后勃起功能的治疗有相似的作用,保留双侧神经的患者,服用西地那非的有72%的成功勃起率(阴道插入);服用伐地那非20 mg和10 mg的反应率是71.1%和59.7%;服用他达拉非的所有患者,平均成功的插入率是54%,平均成功性交率是41%,术后有某种程度勃起的患者,平均成功的插入率和成功性交率是69%和52%.但未有三者对RRP术后ED治疗的直接比较.
The rate of erectile dysfunction after radical retropubic prostatectomy is from 10% to 100%. The prevalence of erectile dysfunction after nerve-sparing radical prostatectomy is more than one third. In the patients who had undergone bilateral NS, 72% responded to sildenafil, 71.7% and 59.7% responded to 20 mg and 10 mg of vardenafil respectively. For all randomized patients who received tadalafil, the mean percentage of successful penetration attempts was 54% and the mean percentage of successful intercourse attempts was 41%. For the subgroup with evidence of postoperative tumescence these values were 69% and 52% ,respectively. No headto-head trials have been performed with sildenafil,vardenafil and tadalafil in treatment of erectile dysfunction after radical prostatectomy.
出处
《中华男科学杂志》
CAS
CSCD
2005年第9期708-712,共5页
National Journal of Andrology
